里格尔制药

US · RIGL #3318 按市值排名

45.97 -1.28 -2.71%

实时 - 追踪5344个代码 - 心跳于51秒前 · 2026-10-16 19:30

关于 Rigel Pharmaceuticals

Rigel 制药, Inc. 运营 as a clinical stage biotechnology company. It discovers and 开发 novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm 专注于 intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's 产品 include Tavalisse, Fostamatinib and R835. Rigel 制药 was 成立 by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is 总部位于 in South San Francisco, CA.

成立时间: 1996
首席执行官: Mr. Raul R. Rodriguez
员工人数: 174
总部地址: South San Francisco, California, United States of America
财年结束日: 12-31
官方网站: rigel.com

公司概况

交易所: US
股票代码: RIGL
市值排名: #3318
市值: 858.71M
流通市值: 682.19M
总股数: 18.68M
流通股数: 14.84M

行业与主题板块

Biotechnology

浏览全部行业与主题板块

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

里格尔制药

关于 Rigel Pharmaceuticals

公司概况

行业与主题板块